Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11300 participants.
Also called NCT06677060
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 11,300 participants
- Sponsor
- Registry
-
NCT06677060 -
2024-514506-32-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT06677060. Randomized; quadruple masking; primary purpose prevention. Start 2025-03-14 (actual); primary completion 2029-12-17 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- Acronym
- Prevent-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Baxdrostat and dapagliflozin
- Intervention (Other)
- Placebo and dapagliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06677060- Content hash
a0c1c9b0aa7c3030cd0880922f548a4b89fc6feef5f3faa3135a042cd6450be3